Literature DB >> 1098350

Testosterone undecanoate: a new orally active androgen.

C Hirschhäuser, C R Hopkinson, G Sturm, A Coert.   

Abstract

Oral testosterone undecanoate (TU) in arachis oil has been evaluated with a view to its possible use as a means of androgen replacement therapy. A single 100 mg dose was found to elevate plasma androgen levels and urinary 17-ketosteroid excretion in 6 normal men. Ninety mg/day and 60 mg/day doses taken by a hypogonadal man resulted in sustained levels of androgen which appeared physiological when measured by radioimmunoassay without chromatography. However, upon separation of the steroids by chromatography it was found that much of the androgen present was in fact dihydrotestosterone not testosterone. Both TU and dihydrotestosterone undecanoate were detected in plasma by gas chromatography and it is suggested that the ester is absorbed as such from the intestine and the unesterified steroid subsequently released by hydrolysis. The convenience of oral administration, the resulting prolonged elevated plasma androgen levels and the probable lack of deleterious effects on the liver may render oral TU of value where androgen replacement therapy is indicated.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1098350     DOI: 10.1530/acta.0.0800179

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  6 in total

1.  Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone.

Authors:  L Tax
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Jul-Sep       Impact factor: 2.441

2.  Bioavailability of oral testosterone in males.

Authors:  H Frey; A Aakvaag; D Saanum; J Falch
Journal:  Eur J Clin Pharmacol       Date:  1979-11       Impact factor: 2.953

3.  Plasma androgens after a single oral dose of testosterone undecanoate.

Authors:  G Geere; J Jones; S M Atherden; D B Grant
Journal:  Arch Dis Child       Date:  1980-03       Impact factor: 3.791

4.  Dietary fat modulates the testosterone pharmacokinetics of a new self-emulsifying formulation of oral testosterone undecanoate in hypogonadal men.

Authors:  Anthony Yin; Eman Alfadhli; Michelle Htun; Robert Dudley; Sandra Faulkner; Laura Hull; Andrew Leung; Rachelle Bross; James Longstreth; Ronald Swerdloff; Christina Wang
Journal:  J Androl       Date:  2012-07-12

5.  Effects of testosterone undecanoate on sexual potency and the hypothalamic-pituitary-gonadal axis of impotent males.

Authors:  O Benkert; W Witt; W Adam; A Leitz
Journal:  Arch Sex Behav       Date:  1979-11

6.  Effects of oral testosterone treatment on myocardial perfusion and vascular function in men with low plasma testosterone and coronary heart disease.

Authors:  Carolyn M Webb; Andrew G Elkington; Mustafa M Kraidly; Niall Keenan; Dudley J Pennell; Peter Collins
Journal:  Am J Cardiol       Date:  2007-12-21       Impact factor: 2.778

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.